257 related articles for article (PubMed ID: 10411657)
1. Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells.
Kusaba H; Nakayama M; Harada T; Nomoto M; Kohno K; Kuwano M; Wada M
Eur J Biochem; 1999 Jun; 262(3):924-32. PubMed ID: 10411657
[TBL] [Abstract][Full Text] [Related]
2. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of hypomethylation status and preferential expression of exogenous human MDR1/PGY1 gene in mouse L cells by YAC mediated transfer.
Kusaba H; Nakayama M; Harada T; Torigoe K; Green ED; Scherer SW; Kohno K; Kuwano M; Wada M
Somat Cell Mol Genet; 1997 Jul; 23(4):259-74. PubMed ID: 9542528
[TBL] [Abstract][Full Text] [Related]
4. Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells.
Ando T; Nishimura M; Oka Y
Leukemia; 2000 Nov; 14(11):1915-20. PubMed ID: 11069027
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias.
Nakayama M; Wada M; Harada T; Nagayama J; Kusaba H; Ohshima K; Kozuru M; Komatsu H; Ueda R; Kuwano M
Blood; 1998 Dec; 92(11):4296-307. PubMed ID: 9834236
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of MDR1 gene in breast cancer: CpG methylation status dominates the stable maintenance of a silent gene.
Sharma D; Vertino PM
Cancer Biol Ther; 2004 Jun; 3(6):549-50. PubMed ID: 15254426
[No Abstract] [Full Text] [Related]
7. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation.
El-Osta A; Kantharidis P; Zalcberg JR; Wolffe AP
Mol Cell Biol; 2002 Mar; 22(6):1844-57. PubMed ID: 11865062
[TBL] [Abstract][Full Text] [Related]
8. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
Kantharidis P; El-Osta A; deSilva M; Wall DM; Hu XF; Slater A; Nadalin G; Parkin JD; Zalcberg JR
Clin Cancer Res; 1997 Nov; 3(11):2025-32. PubMed ID: 9815593
[TBL] [Abstract][Full Text] [Related]
9. Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells.
Jin W; Scotto KW; Hait WN; Yang JM
Biochem Pharmacol; 2007 Sep; 74(6):851-9. PubMed ID: 17662696
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL.
Knutsen T; Mickley LA; Ried T; Green ED; du Manoir S; Schröck E; Macville M; Ning Y; Robey R; Polymeropoulos M; Torres R; Fojo T
Genes Chromosomes Cancer; 1998 Sep; 23(1):44-54. PubMed ID: 9713996
[TBL] [Abstract][Full Text] [Related]
11. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.
Tada Y; Wada M; Kuroiwa K; Kinugawa N; Harada T; Nagayama J; Nakagawa M; Naito S; Kuwano M
Clin Cancer Res; 2000 Dec; 6(12):4618-27. PubMed ID: 11156211
[TBL] [Abstract][Full Text] [Related]
12. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
[TBL] [Abstract][Full Text] [Related]
13. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma.
Chen KG; Lacayo NJ; Durán GE; Wang Y; Bangs CD; Rea S; Kovacs M; Cherry AM; Brown JM; Sikic BI
Genes Chromosomes Cancer; 2002 Aug; 34(4):372-83. PubMed ID: 12112526
[TBL] [Abstract][Full Text] [Related]
14. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo.
Shi Z; Liang YJ; Chen ZS; Wang XW; Wang XH; Ding Y; Chen LM; Yang XP; Fu LW
Cancer Biol Ther; 2006 Jan; 5(1):39-47. PubMed ID: 16319528
[TBL] [Abstract][Full Text] [Related]
15. Re-expression of RASSF1A by 5-Aza-CdR induced demethylation of the promoter region in human biliary tract carcinoma cells.
Zuo S; Chen Y; Xu L; Tang Q; Zou S
J Huazhong Univ Sci Technolog Med Sci; 2007 Jun; 27(3):281-4. PubMed ID: 17641842
[TBL] [Abstract][Full Text] [Related]
16. Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells.
Côté S; Sinnett D; Momparler RL
Anticancer Drugs; 1998 Oct; 9(9):743-50. PubMed ID: 9840718
[TBL] [Abstract][Full Text] [Related]
17. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer.
Baker EK; El-Osta A
Exp Cell Res; 2003 Nov; 290(2):177-94. PubMed ID: 14567978
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
Baker EK; Johnstone RW; Zalcberg JR; El-Osta A
Oncogene; 2005 Dec; 24(54):8061-75. PubMed ID: 16091741
[TBL] [Abstract][Full Text] [Related]
19. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene.
Ohga T; Uchiumi T; Makino Y; Koike K; Wada M; Kuwano M; Kohno K
J Biol Chem; 1998 Mar; 273(11):5997-6000. PubMed ID: 9497311
[TBL] [Abstract][Full Text] [Related]
20. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
Yang B; Yang ZG; Gao B; Shao GG; Li GH
Int J Clin Exp Pathol; 2015; 8(10):12961-6. PubMed ID: 26722491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
